34. Neurofibromatosis Clinical trials / Disease details
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01345136 (ClinicalTrials.gov) | July 1, 2015 | 21/4/2011 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | A Single Arm, Monocenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma | Neurofibromatosis Type 2;Neuroma, Acoustic | Drug: RAD001, everolimus | Jonsson Comprehensive Cancer Center | Novartis Pharmaceuticals | Active, not recruiting | 16 Years | 65 Years | All | 4 | Phase 2 | United States |
| 2 | NCT01880749 (ClinicalTrials.gov) | June 2013 | 11/6/2013 | Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas | Neurofibromatosis Type 2;Vestibular Schwannomas;Meningiomas | Drug: RAD001 | NYU Langone Health | NULL | Completed | 18 Years | N/A | All | 5 | Early Phase 1 | United States |
| 3 | NCT01365468 (ClinicalTrials.gov) | April 2012 | 27/5/2011 | Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) | A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1) | Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 | Drug: Everolimus (RAD001) | Novartis Pharmaceuticals | NULL | Terminated | 6 Years | N/A | All | 9 | Phase 2 | Israel |
| 4 | NCT01490476 (ClinicalTrials.gov) | January 2012 | 30/11/2011 | Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients | A Single Arm, Single Center, Phase II Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis Type 2 - Related Vestibular Schwannoma | Neurofibromatosis 2 | Drug: RAD001 | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 15 Years | N/A | All | 10 | Phase 2 | France |
| 5 | NCT01419639 (ClinicalTrials.gov) | October 2011 | 17/8/2011 | Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 | Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 | Neurofibromatosis Type II | Drug: Everolimus (RAD001) , Afinitor® | New York University School of Medicine | Novartis Pharmaceuticals;The Children's Tumor Foundation | Completed | 3 Years | N/A | All | 10 | Phase 2 | United States |
| 6 | NCT01412892 (ClinicalTrials.gov) | April 2011 | 8/8/2011 | Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery | Neurofibromatosis Type 1;Plexiform Neurofibroma;Neurofibromatoses | Drug: RAD001: Everolimus | Assistance Publique - Hôpitaux de Paris | Novartis | Completed | 18 Years | 60 Years | Both | 30 | Phase 2 | France |
| 7 | EUCTR2016-001563-36-Outside-EU/EEA (EUCTR) | 12/05/2016 | Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) | A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1) | Plexiform Neurofibroma Associated With Neurofibromatosis Type 1;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Votubia Product Name: Everolimus Product Code: RAD001 | Novartis Pharmaceuticals | NULL | NA | Female: yes Male: yes | 26 | Phase 4 | Israel | |||
| 8 | EUCTR2011-002228-42-FR (EUCTR) | 29/08/2011 | N/A | N/A - AFINF2 | MedDRA version: 14.0;Level: PT;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Afinitor Product Name: Afinitor INN or Proposed INN: Evérolimus Other descriptive name: RAD001 | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | France |